EPS for AzurRx BioPharma, Inc. (AZRX) Expected At $-0.23; Msg Networks (MSGN) Shorts Down By 1.32%

January 19, 2018 - By Marie Mckinney

Msg Networks Incorporated (NYSE:MSGN) had a decrease of 1.32% in short interest. MSGN’s SI was 8.43 million shares in January as released by FINRA. Its down 1.32% from 8.54 million shares previously. With 582,800 avg volume, 15 days are for Msg Networks Incorporated (NYSE:MSGN)’s short sellers to cover MSGN’s short positions. The SI to Msg Networks Incorporated’s float is 14%. The stock increased 2.57% or $0.55 during the last trading session, reaching $21.95. About 266,914 shares traded. MSG Networks Inc. (NYSE:MSGN) has 0.00% since January 19, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect AzurRx BioPharma, Inc. (NASDAQ:AZRX) to report $-0.23 EPS on February, 12.After having $-0.28 EPS previously, AzurRx BioPharma, Inc.’s analysts see -17.86% EPS growth. The stock decreased 2.57% or $0.09 during the last trading session, reaching $3.41. About 33,722 shares traded. AzurRx BioPharma, Inc. (NASDAQ:AZRX) has 0.00% since January 19, 2017 and is . It has underperformed by 16.70% the S&P500.

MSG Networks Inc. engages in the sports production, and content development and distribution businesses in the United States. The company has market cap of $1.65 billion. The firm owns and operates MSG Network and MSG+, which are regional sports and entertainment networks. It has a 9.89 P/E ratio. It also operates MSG GO that provides live streaming and video on demand, as well as a Website and social media platforms for its brands.

Among 13 analysts covering The Madison Square Garden Company (NYSE:MSGN), 4 have Buy rating, 1 Sell and 8 Hold. Therefore 31% are positive. The Madison Square Garden Company had 16 analyst reports since September 30, 2015 according to SRatingsIntel. Stifel Nicolaus upgraded it to “Buy” rating and $17 target in Wednesday, September 30 report. The company was upgraded on Friday, December 9 by Guggenheim. Stifel Nicolaus downgraded MSG Networks Inc. (NYSE:MSGN) rating on Tuesday, January 19. Stifel Nicolaus has “Sell” rating and $17.0 target. The firm has “Outperform” rating by Evercore given on Tuesday, April 11. Bank of America reinitiated the stock with “Buy” rating in Tuesday, January 31 report. The firm earned “Sell” rating on Friday, December 16 by Loop Capital. FBN Securities initiated the shares of MSGN in report on Thursday, May 12 with “Sector Perform” rating. The stock of MSG Networks Inc. (NYSE:MSGN) has “Hold” rating given on Thursday, October 1 by Jefferies. As per Wednesday, April 5, the company rating was downgraded by Macquarie Research. As per Wednesday, October 7, the company rating was initiated by Cantor Fitzgerald.

AzurRx BioPharma, Inc., a clinical development stage biopharmaceutical company, engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company has market cap of $39.40 million. The Company’s product pipeline consists of two therapeutic proteins under development, including MS1819, an autologous yeast recombinant lipase, which is in Phase IIa trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase combination of bacterial origin for the prevention of hospital-acquired infections, as well as antibiotic-associated diarrhea. It currently has negative earnings.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>